All the figurative FDA trains are running on time, according to the agency’s leader Marty Makary, M.D. | “I'm proud to report ...

PwC analysts have warned the speedy evolution of the Chinese biotech sector is creating “heightened risks related to IP ...

A new biotech has come roaring to life in Wales with a $140 million series A and a lead candidate ready for phase 2 trials in ...

Immuneering has reported 94% overall survival (OS) at six months in first-line pancreatic cancer, emboldening the biotech to ...

A pair of professional organizations in the U.K. is calling for the biopharma industry and national government to take action ...

Philips is rolling out what it describes as a next-generation point-of-care ultrasound system, designed specifically for ...

Aptose Biosciences has been thrown a financial lifeline by its own CEO while the leukemia-focused biotech scrambles around ...

Dexcom is working to replace some of the receivers that link with its continuous glucose monitoring systems due to a ...

When Eli Lilly snapped up Scorpion Therapeutics' PI3Kα program earlier this year, the deal allowed Scorpion to spin out a new ...

The FDA is introducing a new priority voucher program designed to shorten the drug review process from 10 to 12 months down to one or two months, according to the agency. | The FDA is introducing a ...

The latest clinical win follows a dual set of phase 3 and phase 2 results back in March. In that data drop, Mineralys reported that lorundrostat reduced systolic blood pressure in a late-stage study ...

Ventyx Biosciences has shared phase 2a data on a Parkinson’s disease prospect that has caught the eye of Sanofi. The readout shows the effect of VTX3232 on biomarkers, providing some of the data that ...